IPSCCentury Therapeutics, Inc.同业对比
Century Therapeutics, Inc. 与Biological Products, (No Diagnostic Substances)的逐项对比:市值、估值、增长、盈利能力、质量与总回报,以及在同业组内的排名。所有数值均由引擎从 SEC 申报与延迟行情计算,排名仅为组内排序位置 —— 描述性数据,非投资建议。
完整同业对比
同业组:同 SIC 行业分类 (Biological Products, (No Diagnostic Substances))| 公司 | 市值 | 市盈率(TTM) | 市净率 | 市销率 | 营收同比增长 | 净利同比增长 | 息税前利润率 | 净资产收益率 | 投入资本回报率 | 皮氏 F 值 | 一年总回报 | 股息率 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IPSC本股 | $333M#8 | — | 1.4x#2 | 3.1x#2 | 1556.8%#1 | 92.4%#3 | -15.8%#1 | -4.1%#2 | -9.3%#1 | — | 269.3%#1 | — |
| EDIT | $415M#2 | — | 3.9x#10 | 10.2x#6 | 25.4%#6 | 32.5%#5 | -394.9%#7 | -152.0%#12 | — | — | -9.7%#9 | — |
| OCGN | $361M#3 | — | — | 81.8x#9 | 8.8%#8 | -25.9%#10 | -1425.7%#8 | — | — | — | -24.7%#11 | — |
| AGEN | $354M#4 | 2.6x#3 | — | 3.1x#3 | 10.4%#7 | 98.7%#2 | -17.7%#2 | — | — | — | 71.9%#4 | — |
| XFOR | $353M#5 | 2.5x#2 | 2.3x#8 | 10.1x#5 | 1273.2%#2 | -111.5%#14 | -247.4%#5 | -50.9%#9 | -582.0%#5 | — | 10.0%#8 | — |
| GRML | $454M#1 | — | 7.8x#12 | — | — | -71.6%#12 | — | -18.2%#4 | -14.6%#2 | — | -89.8%#15 | — |
| LXEO | $343M#6 | — | 1.5x#3 | 525.0x#10 | — | -1.7%#8 | -16706.0%#10 | -42.5%#8 | — | — | -23.4%#10 | — |
| CMPX | $341M#7 | — | 2.1x#6 | — | -100.0%#10 | -34.7%#11 | — | -40.0%#7 | — | — | -48.5%#14 | — |
| IKT | $320M#9 | — | 2.1x#7 | — | -100.0%#10 | -75.4%#13 | — | -31.5%#6 | — | — | 49.7%#6 | — |
| SABS | $318M#10 | 14.6x#4 | 1.5x#4 | — | -100.0%#10 | 138.9%#1 | — | 6.2%#1 | — | — | 24.3%#7 | — |
| FATE | $303M#11 | — | 2.0x#5 | 45.6x#8 | -51.2%#9 | 26.8%#6 | -2222.4%#9 | -88.8%#10 | -102.3%#3 | — | 154.3%#3 | — |
| PALI | $278M#12 | 2.5x#1 | 2.3x#9 | — | — | -16.2%#9 | — | -13.8%#3 | — | — | 167.6%#2 | — |
| LCTX | $259M#13 | — | 4.3x#11 | 17.8x#7 | 53.2%#5 | -241.4%#16 | -251.6%#6 | -104.3%#11 | — | — | -33.4%#12 | — |
| STRO | $253M#14 | — | — | 2.5x#1 | 65.2%#4 | 15.9%#7 | -154.5%#4 | — | — | — | 68.6%#5 | — |
| LIMN | $243M#15 | — | 808.8x#13 | — | — | -187.8%#15 | — | -3395.2%#13 | -170.3%#4 | — | -94.5%#16 | — |
| IVVD | $224M#16 | — | 1.2x#1 | 4.2x#4 | 110.5%#3 | 69.1%#4 | -104.0%#3 | -29.0%#5 | — | — | -39.2%#13 | — |
数值来自 SEC 申报与延迟行情;排名仅为该组内的排序位置 —— 描述性数据,不构成评级或建议。 数据构建于 2026-09-19。
数据来自 SEC XBRL 申报与延迟行情 · 排名为组内排序 · 仅供参考 · 非投资建议